Eterna Therapeutics
ERNA
7 hedge funds and large institutions have $9.9M invested in Eterna Therapeutics in 2014 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and closing their positions.
40% more funds holding
Funds holding: 5 → 7 (+2)
8.92% more ownership
Funds ownership: 12.71% → 21.63% (+8.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AWMDMG
Austin W. Marxe & David M. Greenhouse
New York
|
+$4.83M |
| 2 |
Eagle Asset Management
St Petersburg,
Florida
|
+$440K |
| 3 |
PCM
Perritt Capital Management
Chicago,
Illinois
|
+$440K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$440K |
Top Sellers
ERNA Hedge Fund Activity: Q2 2014 in Review
7 of the 3,491 institutional investors tracked by Wall St. Rank reported a position in Eterna Therapeutics (ERNA) for Q2 2014, worth a combined $9.9M — up 73% from $5.69M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new ERNA positions and 0 closed out — a net gain of 3 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Austin W. Marxe & David M. Greenhouse, opening a new position worth an estimated $4.83M.
- 7 institutional investors held Eterna Therapeutics (ERNA) as of Q2 2014, up from 5 in Q1 2014.
- Funds reported $9.9M of Eterna Therapeutics stock for Q2 2014, up 73% quarter-over-quarter.
- 3 funds opened new Eterna Therapeutics positions in Q2 2014 and 0 closed out, a net change of +3 holders.
- The largest Eterna Therapeutics buyer in Q2 2014 was Austin W. Marxe & David M. Greenhouse, an estimated $4.83M added.
Based on aggregated 13F filings for Q2 2014.